Exploring Syndax Pharmaceuticals, Inc. (SNDX) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on Syndax Pharmaceuticals (SNDX) and wondering who's investing and what's driving their decisions? As of December 31, 2024, a total of 421 institutional owners and shareholders have filed 13D/G or 13F forms with the SEC, holding a cumulative of 109,066,763 shares. Major players like BlackRock, Inc., Kynam Capital Management, LP, and Goldman Sachs Group Inc are among the top shareholders. But with Syndax Pharmaceuticals' stock experiencing a 46.76% decline between April 16, 2024, and April 15, 2025, and a Q4 2024 net loss of $94.2 million, what's the sentiment driving these investment decisions? Dive in to explore the dynamics of SNDX's investor profile and uncover the factors influencing their strategies.

Syndax Pharmaceuticals, Inc. (SNDX) Who Invests in [Company Name] and Why?

Understanding the investor profile of Syndax Pharmaceuticals, Inc. (SNDX) provides insights into market sentiment and the factors driving investment decisions. A diverse investor base can contribute to stock stability, while concentrated ownership may lead to higher volatility. As of April 2025, the ownership structure of SNDX includes a mix of institutional, retail, and individual investors.

Institutional investors, mutual funds, hedge funds, individual investors, financial professionals, business strategists, and academic stakeholders constitute the main categories of investors in Syndax Pharmaceuticals. Each type of investor has different motivations and strategies.

• Institutional Investors: These include financial holdings companies, banks, insurance companies, mutual fund managers, portfolio managers, and self-managed pension and endowment funds. Major institutions are defined as those that exercise investment discretion over assets exceeding $100 million. As of December 31, 2024, institutional ownership in Syndax Pharmaceuticals was significant.
• Retail Investors: These are individual investors who buy and sell securities for their own accounts, and are not considered professional investors.
• Hedge Funds: These are investment partnerships that use pooled funds and employ different strategies to earn active return, or alpha, for their investors.

According to Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX)., the institutional ownership of Syndax Pharmaceuticals is substantial. Fintel reports that Syndax Pharmaceuticals, Inc. (US:SNDX) has 421 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 109,066,763 shares.

Key institutional holders include:

• BlackRock, Inc.
• Kynam Capital Management, LP
• Goldman Sachs Group Inc.
• Morgan Stanley
• Vanguard Group Inc.
• Wellington Management Group Llp
• State Street Corp
• VGHCX - Vanguard Health Care Fund Investor Shares
• StemPoint Capital LP
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares

These institutions file reports with the SEC, providing insights into their holdings and transactions. These reports are limited to equity securities, including common stock and equivalents, convertible preferred stock, and convertible bonds. They do not include fixed income, real estate, or cash equivalents.

Several factors attract investors to Syndax Pharmaceuticals:

• Growth Prospects: Syndax is a commercial-stage biopharmaceutical company with a focus on developing and marketing cancer therapies. The company's pipeline includes Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody.
• Market Position: Syndax has a strong market position with its two first-in-class medicines, Revuforj and Niktimvo, addressing major unmet needs in acute leukemia and chronic graft-versus-host disease (GVHD).

Syndax Pharmaceuticals' investors employ various strategies, including:

• Long-Term Holding: Some institutions, such as Vanguard and BlackRock, often adopt a long-term holding strategy, maintaining their positions for extended periods.
• Short-Term Trading: Hedge funds and other active managers may engage in short-term trading to capitalize on price fluctuations.
• Value Investing: Some investors may see Syndax as undervalued, considering its growth potential and recent market performance.

Analysts are generally bullish on Syndax, with many assigning 'Buy' ratings. For example, as of April 2025, 12 Wall Street analysts have offered 12-month price targets for Syndax Pharmaceuticals stock with an average target of $34.20. The average target predicts an increase of 209.50% from the current stock price of $11.05.

Syndax reported $7.7 million in Revuforj net product revenue in the initial five weeks of launch during the fourth quarter of 2024. With approximately $692.4 million in cash, cash equivalents, and investments, Syndax expects to fund operations to profitability.

The ownership structure of Syndax Pharmaceuticals reflects a mix of institutional, retail, and individual investors. Institutional investors hold a significant percentage of the company's stock. The diversity in investment strategies and motivations highlights the complex dynamics influencing Syndax's market performance.

Syndax Pharmaceuticals, Inc. (SNDX) Institutional Ownership and Major Shareholders of Syndax Pharmaceuticals, Inc. (SNDX)

Institutional ownership in Syndax Pharmaceuticals, Inc. (SNDX) plays a crucial role in shaping the company's stock performance and strategic direction. Examining the major shareholders and their recent activities provides valuable insights for investors.

As of Q4 2023:

• The total value of stock holdings in SNDX is $368.494 million.
• The number of institutional owners is 237.
• The number of shares held by institutions is 18,496,664.

Here’s a detailed look at some of the top institutional investors in Syndax Pharmaceuticals, Inc. (SNDX) and their respective holdings:

• Vanguard Group Inc: Holds 3,371,684 shares, representing 17.28% ownership.
• Blackrock Inc: Holds 2,871,108 shares, representing 14.71% ownership.
• State Street Corp: Holds 1,036,636 shares, representing 5.32% ownership.
• RA Capital Management, L.P.: Holds 999,999 shares, representing 5.13% ownership.
• FMR LLC: Holds 948,400 shares, representing 4.86% ownership.
• Geode Capital Management, LLC: Holds 535,646 shares, representing 2.75% ownership.
• Nikko Asset Management Americas, Inc.: Holds 483,700 shares, representing 2.48% ownership.
• Dimensional Fund Advisors LP: Holds 479,543 shares, representing 2.46% ownership.
• Invesco Ltd.: Holds 467,757 shares, representing 2.40% ownership.
• Point72 Asset Management, L.P.: Holds 339,400 shares, representing 1.74% ownership.

The table below summarizes the top 10 institutional holders of Syndax Pharmaceuticals, Inc. (SNDX) as of Q4 2023:

Recent Changes in Ownership

Monitoring changes in institutional ownership can indicate shifts in sentiment and potential future stock performance. For instance:

• RA Capital Management, L.P. decreased their holdings by 32% in the last quarter, selling 475,001 shares.
• Point72 Asset Management, L.P. increased their holdings by 32% in the last quarter, buying 82,400 shares.

These adjustments in positions by major institutional investors can sometimes precede significant movements in the stock price.

Impact of Institutional Investors

Institutional investors wield considerable influence over Syndax Pharmaceuticals, Inc. (SNDX) due to the size of their holdings. Their actions can impact:

• Stock Price: Large purchases can drive the price up, while significant sales can exert downward pressure.
• Company Strategy: Institutions often engage with company management regarding strategic decisions, influencing the direction of the company.
• Stability: High institutional ownership can provide stability to the stock due to the long-term investment horizons of many institutions.

Understanding the ownership structure and the behaviors of these major players is essential for anyone investing in Syndax Pharmaceuticals, Inc. (SNDX). To further evaluate the financial health of the company, consider exploring Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors.

Syndax Pharmaceuticals, Inc. (SNDX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Syndax Pharmaceuticals, Inc. (SNDX) provides valuable insights into the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance through their holdings and actions.

While specific, real-time data on all investors and their recent moves can fluctuate rapidly and may not always be publicly available, we can discuss general categories of investors and illustrative examples based on available information and reporting norms.

Notable Investors:

Institutional investors, hedge funds, and private equity firms often hold significant stakes in pharmaceutical companies like Syndax Pharmaceuticals, Inc. (SNDX). These investors conduct extensive research and analysis before investing, and their actions can significantly impact the company's stock price and strategic direction.

• Vanguard Group: Typically holds a substantial position in many publicly traded companies.
• BlackRock Fund Advisors: Another major institutional investor with broad holdings.
• RA Capital Management, L.P.: A healthcare-focused investment firm.

Investor Influence:

Large institutional investors often have the resources and expertise to engage with company management and influence corporate strategy. They may participate in shareholder votes, propose changes to the company's board of directors, or advocate for specific business initiatives. Activist investors, in particular, may seek to drive significant changes in a company's operations or strategic direction to unlock value.

The influence of these investors can manifest in several ways:

• Strategic shifts: Investors might push for changes in R&D focus or business development strategies.
• Operational improvements: Demands for greater efficiency or cost reduction.
• Governance changes: Suggestions for board restructuring or executive compensation adjustments.

Recent Moves:

Keep an eye on SEC filings (such as 13F filings) to track the recent buying and selling activity of major investors. These filings provide a quarterly snapshot of institutional investment positions. News articles and financial analysis reports often highlight significant investment moves that could affect stock prices.

For example, significant increases or decreases in holdings by major investors can signal confidence or concern about the company's future prospects. Public statements or activist campaigns by these investors can also create short-term volatility in the stock price.

Here is a hypothetical example of how to interpret institutional ownership data:

These numbers are purely illustrative and do not reflect the actual holdings of these firms in Syndax Pharmaceuticals, Inc. (SNDX). Always consult official SEC filings and reputable financial news sources for accurate data.

Understanding who invests in Syndax Pharmaceuticals, Inc. (SNDX) and why can provide valuable context for assessing the company's potential. Monitoring their moves and understanding their motivations can offer insights into the future direction of the company.

See also: Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).

Syndax Pharmaceuticals, Inc. (SNDX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to ownership changes is crucial for gauging the future trajectory of Syndax Pharmaceuticals, Inc. (SNDX). Shifts in major shareholdings can significantly influence stock prices and overall market confidence. Examining recent market behavior in response to investor activities provides valuable insights into how the financial community perceives the company's prospects.

Analyst perspectives further enrich this understanding by offering expert opinions on how key investors might shape Syndax Pharmaceuticals, Inc.'s strategic direction and long-term success. These insights help current and potential investors make informed decisions, assessing not only the company's intrinsic value but also the potential impact of significant investor actions.

Here's a look at some key aspects of investor sentiment, market reactions, and analyst perspectives concerning Syndax Pharmaceuticals, Inc. (SNDX):

• Investor Sentiment: Gauging the overall attitude of major shareholders towards Syndax Pharmaceuticals, Inc. (SNDX) helps in understanding potential long-term stability and commitment. Positive sentiment typically correlates with increased investment and confidence in the company's strategic direction.
• Recent Market Reactions: Monitoring how the stock market responds to changes in ownership, especially large investor moves, provides insights into market confidence and perceived value. Significant stock price fluctuations following these changes can indicate the market's assessment of these moves.
• Analyst Perspectives: Analyzing insights from financial analysts on the impact of key investors offers professional evaluations of how these investors might influence Syndax Pharmaceuticals, Inc.'s future. These perspectives often include predictions on company performance and strategic shifts.

Recent ownership trends can offer clues about the future direction of Syndax Pharmaceuticals, Inc. (SNDX). For example, a surge in institutional ownership might signal strong confidence in the company's long-term prospects, while a decrease could indicate concerns or a shift in investment strategy.

To illustrate the dynamics, consider a hypothetical scenario where a major institutional investor significantly increases their stake in Syndax Pharmaceuticals, Inc. (SNDX). The market reaction could be positive, with the stock price climbing as other investors interpret this move as a vote of confidence. Analysts might then weigh in, suggesting that this increased investment could lead to accelerated research and development efforts or strategic partnerships.

Conversely, if a major investor reduces their position, the market might react negatively, with the stock price declining. Analysts could then explore the reasons behind the divestment, potentially highlighting concerns about clinical trial results or market competition. Keeping abreast of these changes is vital for stakeholders.

Examining analyst ratings and price targets provides additional context. Upgrades or positive ratings from analysts often reflect optimism about Syndax Pharmaceuticals, Inc.'s (SNDX) future, while downgrades may signal concerns. Price targets offer a benchmark for the stock's potential value, based on analysts' assessments of the company's financial performance and market conditions.

For example, analysts might set a higher price target if they anticipate successful drug approvals or strong sales growth, influenced by strategic investments from key shareholders. Conversely, a lowered price target could reflect concerns about regulatory hurdles or market challenges.

Understanding the interplay between investor sentiment, market reactions, and analyst perspectives provides a comprehensive view of the factors influencing Syndax Pharmaceuticals, Inc.'s (SNDX) market performance. This holistic approach enables investors to make well-informed decisions, grounded in both quantitative data and qualitative insights.

Here is a link that provides more insights into Syndax Pharmaceutical's mission, vision and core values: Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).